KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Capital Expenditures (2016 - 2022)

TherapeuticsMD's Capital Expenditures history spans 12 years, with the latest figure at -$21000.0 for Q2 2022.

  • For Q2 2022, Capital Expenditures fell 151.22% year-over-year to -$21000.0; the TTM value through Sep 2022 reached $21000.0, down 89.6%, while the annual FY2021 figure was $34000.0, 83.57% down from the prior year.
  • Capital Expenditures reached -$21000.0 in Q2 2022 per TXMD's latest filing, down from $42000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $996909.0 in Q3 2019 to a low of -$70000.0 in Q3 2021.
  • Average Capital Expenditures over 5 years is $172296.5, with a median of $41000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 4745.24% in 2019, then tumbled 638.46% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $150745.0 in 2018, then surged by 139.2% to $360587.0 in 2019, then plummeted by 53.41% to $168000.0 in 2020, then tumbled by 141.67% to -$70000.0 in 2021, then skyrocketed by 70.0% to -$21000.0 in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Capital Expenditures are -$21000.0 (Q2 2022), $42000.0 (Q1 2022), and -$70000.0 (Q3 2021).